STAT
Some telehealth companies now market branded and compounded GLP-1s for alcohol use disorder. Experts quoted by STAT worry about fragmented care for an unproven use.
Recap by typeshit. Full story at STAT.
Osbourne says any medicine can be misused and connects Ozempic to the body image struggles he had when he was younger.
A one-line stock move for the maker of Mounjaro and Zepbound, with no reason given for the gain.
29:53
Journalist Scott Carney argues in favor of gray-market peptides. Only the title is available, so watch for his full reasoning and treat any health claims with caution.
The company announced exclusive manufacturing rights across its needle-free peptide products. Terms aren't given here.
The rise was driven by new generics and steady prices, with Eli Lilly's tirzepatide named in the market breakdown.
The roundup also covers telehealth firms marketing off-label GLP-1s for addiction and a Treasury rule adding scrutiny to licensing deals with Chinese biotechs.
Loading…